

**Anti-IL-22 Reference Antibody (fezakinumab)  
Recombinant Antibody  
Catalog # APR10162****Specification**

---

**Anti-IL-22 Reference Antibody (fezakinumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">O9GZX6</a>
Reactivity	Rat, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.84 KDa

**Anti-IL-22 Reference Antibody (fezakinumab) - Additional Information****Target/Specificity**  
IL-22**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-IL-22 Reference Antibody (fezakinumab) - Protein Information****Name** IL22**Synonyms** ILTIF, ZCYTO18**Function**  
Cytokine that plays a critical role in modulating tissue responses during inflammation (PubMed:<a href="http://www.uniprot.org/citations/17204547" target="\_blank">17204547</a>). Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage (PubMed:<a href="http://www.uniprot.org/citations/17204547" target="\_blank">17204547</a>). Unlike most of the cytokines, has no effect on immune cells. Signals through a heterodimeric receptor composed of two subunits, the specific receptor IL22RA1 which is present on non-immune cells in many organs and the shared subunit IL10RB (PubMed:<a href="http://www.uniprot.org/citations/10875937" target="\_blank">10875937</a>, PubMed:<a href="http://www.uniprot.org/citations/18599299" target="\_blank">18599299</a>). Ligand of

IL22RA1 with IL22 induces activation of the tyrosine kinases JAK1 and TYK2, which in turn activates STAT3. In turn, promotes cell survival and proliferation through STAT3, ERK1/2 and PI3K/AKT pathways (PubMed: [25793261](http://www.uniprot.org/citations/25793261), PubMed: [31311100](http://www.uniprot.org/citations/31311100)). Promotes phosphorylation of GSK3B at 'Ser-9' and CTTN (By similarity). Promotes epithelial cell spreading (By similarity).


**Cellular Location**  
Secreted.

### Anti-IL-22 Reference Antibody (fezakinumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-IL-22 Reference Antibody (fezakinumab) - Images



Anti-IL-22 Reference Antibody (fezakinumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-22 Reference Antibody (fezakinumab) is more than 99.05%, determined by SEC-HPLC.



Immobilized human IL 22, Fc Tag at 2 µg/mL can bind Anti-IL-22 Reference Antibody (fezakinumab)  $\square$  EC50=0.103 µg/mL